scholarly journals RECURRENT ISCHEMIC STROKE IN A CANNABIS USER UNDER 30: A CASE REPORT

2021 ◽  
Vol 9 (10) ◽  
pp. 287-291
Author(s):  
K. Benallel ◽  
◽  
D. Nzamba ◽  
R. Benjelloun ◽  
M. Gartoum ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Case Report ◽  
Cerebrovascular Disease ◽  
Young Patients ◽  
Cannabis Use ◽  
Cannabis User

Cerebrovascular disease is one of the overlooked complications of cannabis use. In young patients presenting with symptoms of ischemic stroke, the recent use of cannabinoids should be systematically investigated. Yet, cannabis use is widespread and some countries have taken further steps to legalize it. Here we present the case of a 29-year-old patient who had two several ischemic strokes within two months, each time after an important cannabis ingestion. This case illustrates the role cannabis can play in ischemic strokes occurring in young patients even though the pathophysiology of such an implication is not totally elucidated.

Delayed Thrombus on Carotid Web: Case Report With Escalation of Treatment

2021 ◽  
pp. 194187442110589
Author(s):  
Thomas V. Kodankandath
Keyword(s):  
Ischemic Stroke ◽  
Case Report ◽  
Carotid Artery ◽  
Acute Ischemic Stroke ◽  
Ct Angiography ◽  
Stent Placement ◽  
Young Patients ◽  
Carotid Stenting ◽  
Definitive Treatment ◽  
Carotid Wall

Carotid artery web is an underrecognized source and is found in about 1-2% of patients with acute ischemic stroke. Although, first described four decades ago, optimal therapy for carotid web is not yet known. Carotid stenting and endarterectomy are increasingly used for carotid web treatment, given its definitive treatment and avoiding the complications associated with anticoagulation. The case reported here is of an ischemic stroke secondary to a mobile thrombus on a carotid web evident on CT angiography and successful definitive treatment with delayed carotid wall stent placement. In young patients who have a diagnosis of ischemic stroke, the carotid web should be on the differential and adequate neuroimaging with either CTA or DSA should be pursued.

Cerebrovascular Disease in Young Patients

1997 ◽  
Vol 78 (01) ◽  
pp. 013-023 ◽  
Author(s):  
James Grotta
Keyword(s):  
Cerebrovascular Disease ◽  
Young Patients

An Uncommon Presentation of Polycythemia Vera as Ischemic Stroke—A Rare Case Report

2012 ◽  
Vol 3 (5) ◽  
pp. 455-457
Author(s):  
Dr .KOUSHIK GUDAVALLI ◽  
◽  
Dr .SHILPA CHIKATI ◽  
Dr .MOHAN RAO JAKKAMPUTI ◽  
Dr .KAMAL LOCHAN BEHERA ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Case Report ◽  
Polycythemia Vera ◽  
Rare Case ◽  
Uncommon Presentation ◽  
Rare Case Report

Delayed recurrence of neonatal HSV-2 encephalitis after 21 years, complicated by ischemic stroke: a case report

2021 ◽  
Author(s):  
Muhammad Qasim ◽  
César E. Escamilla-Ocañas ◽  
Chethan P. Venkatasubba Rao
Keyword(s):  
Ischemic Stroke ◽  
Case Report

scholarly journals Impacts of treatments on recurrence and 28-year survival of ischemic stroke patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Ting-Ann Wang ◽  
Tzy-Haw Wu ◽  
Shin-Liang Pan ◽  
Hsiu-Hsi Chen ◽  
Sherry Yueh-Hsia Chiu
Keyword(s):  
Ischemic Stroke ◽  
Cerebrovascular Disease ◽  
Cox Regression ◽  
Controlled Trial ◽  
Stroke Recurrence ◽  
Long Term Effects ◽  
Stroke Patients ◽  
Double Blind ◽  
Term Survival

AbstractAspirin and nicametate are well-established therapies for preventing recurrence and mortality from stroke in patients diagnosed as ischemic stroke. However, their respective effects on the recurrence, making allowance for the duration of recurrence and death without the occurrence of recurrence, and long-term survival have not been well elucidated. We aimed to evaluate long-term effect of two kinds of treatment on cerebrovascular death among ischemic stroke patients with or without the recurrence of stroke. Data used in this study were derived from the cohort based on a multicenter randomized double-blind controlled trial during 1992 to 1995 with the enrollment of a total of 466 patients with first-time non-cardioembolic ischemic stroke who were randomly allocated to receive aspirin (n = 222) or nicametate (n = 244). The trial cohort was followed up over time to ascertain the date of recurrence within trial period and death until Sep of 2019. The time-dependent Cox regression model was used to estimate the long-term effects of two treatments on death from cerebrovascular disease with and without recurrence. A total of 49 patients experienced stroke recurrence and 89 cerebrovascular deaths was confirmed. Patients treated with nicametate were more likely, but non statistically significantly, to have recurrence (aHR: 1.73, 95% CI 0.96–3.13) as compared with those treated by aspirin. Nicametate reduced the risk of cerebrovascular death about 37% (aHR: 0.63, 95% CI 0.41–0.97) compared with aspirin. The aspirin group had a lower recurrence rate than the nicametate group even with recurrence after 1–2 years of follow-up of first stroke but the latter had significantly reduced death from cerebrovascular disease for nicametate group, which requires more research to verify.

Factor V Leiden Mutation in Cerebrovascular Disease

2005 ◽  
Vol 11 (3) ◽  
pp. 339-342 ◽  
Author(s):  
Nur Buyru ◽  
Julide Altinisik ◽  
Goksel Somay ◽  
Turgut Ulutin
Keyword(s):  
Ischemic Stroke ◽  
Intracerebral Hemorrhage ◽  
Cerebrovascular Disease ◽  
Smoking Status ◽  
Factor V Leiden ◽  
Restriction Enzyme Digestion ◽  
Factor V ◽  
Mutation Site ◽  
Factor V Leiden Mutation ◽  
High Prevalence

Several studies indicate a high prevalence of factor V Leiden mutation as the most frequent coagulation defect found in patients with venous thrombosis. The relationship between this mutation and cerebrovascular disease has not been established in adults. In this investigation, we studied 29 patients with ischemic stroke and 20 with intracerebral hemorrhage, all of whom were compared with 20 controls. A region of the factor V gene containing the Leiden mutation site was amplified with polymerase chain reaction and the presence of mutation was determined with restriction enzyme digestion. We found no evidence of an association between factor V Leiden mutation and ischemic stroke or intracerebral hemorrhage. There was no evidence of association in subgroup the analysis by age, smoking status, myocardial infarction, hypertension, diabetes mellitus, or coronary disease. Factor V Leiden mutation doesn’t seem to be associated with a risk of cerebrovascular disease.

Sign in / Sign up

Export Citation Format

Share Document